OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Shanghai Fosun Pharmaceutical (Group) Co OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shanghai Fosun Pharmaceutical (Group) Co OCF Yield % Related Terms
Shanghai Fosun Pharmaceutical (Group) Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co OCF Yield % Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co OCF Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a OCF Yield % of 8.96 as of Jul. 06, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 120% above median its historical median of 4.08. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's OCF Yield % has ranged from 1.35 to 9.48. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #232 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Shanghai Fosun Pharmaceutical (Group) Co's OCF Yield % too high?
Shanghai Fosun Pharmaceutical (Group) Co's current OCF Yield % of 8.96 is 120% above median its 10-year median of 4.08. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 9.48. The Drug Manufacturers industry median OCF Yield % is 3.39. Shanghai Fosun Pharmaceutical (Group) Co's value of 8.96 is 164.3% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #232 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #232 out of 1005 companies for OCF Yield %. This places Shanghai Fosun Pharmaceutical (Group) Co in the top 23% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.39. Shanghai Fosun Pharmaceutical (Group) Co's value of 8.96 is 164.3% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own OCF Yield % has ranged from 1.35 to 9.48 over the past decade. While the company's 10-year median is 4.08 vs. the industry median of 3.39, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.39, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current OCF Yield % of 8.96 is 164.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current OCF Yield % is 8.96, which is 120% above median its own 10-year median of 4.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.11, compared to a current price of ¥24.08 — trading 11.2% below its estimated fair value. The current OCF Yield % is 8.96, which is 120% above median its 10-year median of 4.08 and 164.3% above the Drug Manufacturers industry median of 3.39. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current OCF Yield % is 8.96 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥24.08 is trading 11.2% below its estimated GF Value™ of ¥27.11.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
OCF Yield %: 8.96 (120% above median its 10-year median of 4.08)
GF Value™: ¥27.11 vs. price of ¥24.08 (11.2% below fair value)
Industry Position: 164.3% above the Drug Manufacturers median (#232 of 1005)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SHSE:600196
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
